Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
Public ClinicalTrials.gov record NCT05192889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
Study identification
- NCT ID
- NCT05192889
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Enrollment
- 35 participants
Conditions and interventions
Interventions
- Blinatumomab Biological
- Calaspargase Pegol Drug
- Cyclophosphamide Drug
- Cytarabine Drug
- Dasatinib Drug
- Dexamethasone Drug
- Erwinia asparaginase Drug
- Etoposide Drug
- Intrathecal Triples Drug
- Leucovorin Drug
- Mercaptopurine Drug
- Methotrexate Drug
- Navitoclax Drug
- Pegaspargase Drug
- Radiation Radiation
- Venetoclax Drug
- Vincristine Drug
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 4 Years to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2022
- Primary completion
- Jun 12, 2024
- Completion
- Jan 31, 2027
- Last update posted
- Sep 21, 2025
2022 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05192889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05192889 live on ClinicalTrials.gov.